# Cancer as a Genetic Disease

> Cell lineages expand when their DNA changes improve growth or survival. Every change a lineage carries, driver or passenger, spreads with it. Most cancer-associated changes arise in body cells during life rather than being inherited; oncogene activation and tumor-suppressor loss can give a lineage an advantage, loss of heterozygosity can supply a second hit, and mutation plus selection can build a branching tumor. Tumor and matched-normal sequencing then help place variants as germline, somatic, clonal or subclonal.

Course: Genetics and Molecular Biology (From gene to protein, and its control). Level: core university (third year). About 22 minutes.
Lesson page (link this one when citing): https://stemhop.com/lessons/cancer-genetics/

Builds on: Reading Pedigrees: Human Inheritance · DNA Repair and Recombination · Mutation: Where Variation Comes From

## What you'll learn

- Explain why cancer is a genetic disease but usually not an inherited one: acquired changes accumulate, drivers give a cell lineage a selective advantage, and passengers ride along without one.
- Distinguish oncogenes (gain of function, one altered allele usually enough in the cell) from tumor-suppressor genes (loss of function, usually both alleles lost), with RAS, MYC, RB1 and TP53 as examples.
- Explain why an inherited tumor-suppressor allele is dominant in a pedigree but recessive in the cell, using Knudson's two-hit hypothesis for retinoblastoma.
- Describe how loss of heterozygosity, by deletion, chromosome loss or mitotic recombination, often supplies the second hit.
- Explain how genome instability and clonal selection drive tumor evolution, and interpret variant allele fractions from tumor and matched-normal sequencing.

The first film followed one somatic change through a dividing lineage. A **somatic** change arises in a body cell during life and passes to its daughters, but usually not to the person’s children. A **germline** change comes through the egg or sperm, is usually in every cell, and can be inherited. A **driver** gives its cell a selective advantage. A **passenger** gives none.

**The one idea:**

Cell lineages expand when their DNA changes improve growth or survival. Every change a lineage carries, driver or passenger, spreads with it.

**Scope:**

This rule describes selection among somatic cell lineages within a tissue. It does not say that every DNA change helps, that every expanding lineage owes its growth to selection, that every selected clone becomes cancer, or that every cancer follows one fixed sequence.

## Two kinds of cancer gene: accelerators and brakes

The first film set the one-copy and two-copy rules; here are the molecules behind them, then the exceptions. One change alone usually does not make a malignant cancer.

*Figure (AI-generated illustration).* An oncogene is an accelerator stuck on, so one altered copy is usually enough. A tumor suppressor is a brake, and one working copy usually still holds, so a cell must normally lose both copies before it divides unchecked. Image: three panels, each with a cell holding two gene copies. With one altered oncogene copy the cell divides; with one working copy of a tumor suppressor the cell is held back; with both tumor-suppressor copies lost the cell divides. Simple pedal shapes mark a stuck accelerator and a working or cracked brake.

A **proto-oncogene** is a normal gene whose product drives growth or division; an **oncogene** is its altered, overactive form, a gain of function dominant within the cell.

RAS is a switch: on while it holds GTP, off once it hydrolyzes GTP to GDP. A one-base change in HRAS from a human bladder carcinoma line replaces glycine with valine at codon 12. Purified Val12 protein hydrolyzed GTP several times more slowly than normal HRAS made in *E. coli*. The larger effect: a GTPase-activating protein, or GAP, sped hydrolysis by normal RAS more than 200-fold but did not speed codon 12 mutants (signaling in the [oncogenes](https://stemhop.com/lessons/oncogenes/) and [RAS-to-MAPK](https://stemhop.com/lessons/ras-to-mapk/) lessons).

**Predict.** If a RAS mutant ignores the GAP that normally speeds its off reaction, does it spend more or less time in the GTP-bound state?

> **Check your prediction.** More time. Without GAP speeding its off reaction, the mutant stays GTP-bound, and on, longer.

MYC is usually activated another way: by extra copies (amplification) or by a translocation that puts it under the control of a highly active gene’s regulatory DNA. In Burkitt lymphoma the commonest change is t(8;14), which places MYC beside an immunoglobulin heavy-chain gene (see [chromosome changes](https://stemhop.com/lessons/chromosome-changes/)).

A **tumor-suppressor gene** encodes a brake: its product restrains division or stops a damaged cell. Losing both alleles, a change recessive within the cell, can help a cell become cancerous, usually together with other changes.

RB1 encodes RB. In its underphosphorylated form, RB binds E2F transcription factors that turn on genes for DNA replication. Returning a cloned RB gene to RB-deficient human tumor cells suppressed their tumor-like growth in a 1988 test. TP53 encodes p53, which accumulates after DNA damage and can halt the cell cycle or trigger cell death (see [stress signals](https://stemhop.com/lessons/stress-signals/) and [death receptors and BCL-2](https://stemhop.com/lessons/death-receptors-bcl2-caspases/)).

The first film’s paradox, an *RB1* allele dominant in a family yet recessive in a cell, rests on pedigree terms: the allele shows **autosomal dominant** inheritance: about half a carrier’s children inherit the risk, and affected people can appear generation after generation (see [reading pedigrees](https://stemhop.com/lessons/pedigrees/)). Both hold because a pedigree tracks risk, and a carrier has very many cells that each already have one hit, so a second hit in at least one is likely. **Penetrance**, the fraction of carriers who show the trait, is therefore high but below 100%.

p53 shows two exceptions to the copy rules. It acts as a tetramer, and many TP53 missense mutant proteins can disable wild-type subunits they join, a dominant-negative effect. In mice with one p53-null allele, many tumors kept a functional wild-type allele, so reduced dose may suffice in that model.

**Predict.** If mutant p53 disables a tetramer that also contains wild-type subunits, must both TP53 alleles be lost before function falls?

> **Check your prediction.** Not necessarily. A mutant subunit can interfere with wild-type subunits in the same tetramer.

## Retinoblastoma and the two-hit arithmetic

Retinoblastoma is a tumor of the developing retina. Hereditary cases tend to be bilateral (both eyes) and diagnosed earlier; nonhereditary cases usually involve one tumor in one eye. Most hereditary cases lack a family history because the mutation arose new, most often in the father’s sperm, and some carriers have a tumor in only one eye.

The first film’s two routes come from Alfred Knudson. In 1971 he analysed 48 cases with published series and concluded that two events are needed. He estimated that carriers develop about three tumors on average, not a whole retina of tumor. Knudson did not find the gene; Stephen Friend and colleagues isolated a cDNA from the chromosome 13 *RB1* locus in 1986.

A simple model shows what the two hits predict. If each tumor in a carrier arises from an independent second hit, tumors per eye follow a Poisson distribution. With about three tumors per carrier and independent eyes, about 5% of carriers have no tumor, so penetrance is about 95%, and most affected carriers have bilateral disease (full calculation under Going deeper).

**Predict.** Under this model, is a carrier more likely to have tumors in both eyes or in one eye only?

> **Check your prediction.** Both eyes: about 60% of carriers, against about 35% with one eye only.

In a nonhereditary case, both rare hits must fall in one lineage, so the expected number of tumors per eye is far below 1. Such tumors tend to be single, one-sided and diagnosed later.

*Interactive on the lesson page:* Two hits or one — who gets retinoblastoma, and when

## How the second hit happens: loss of heterozygosity

A carrier is **heterozygous** at *RB1*: one mutant allele and one wild-type allele. A second hit can be a new point mutation in the wild-type allele or silencing of its promoter by DNA methylation (see [eukaryotic regulation](https://stemhop.com/lessons/eukaryotic-regulation/)).

Often it is larger. **Loss of heterozygosity** (LOH) means that a site no longer has two different allele identities. In a carrier’s tumor, only the mutant identity remains. The cell may keep one physical copy, after a deletion or chromosome loss, or two matching copies, after loss and duplication of the mutant chromosome or after **mitotic recombination**, a crossover between homologs in a dividing body cell that leaves a daughter cell with two copies of the mutant region.

**Predict.** A tumor retains two copies of chromosome 13 but shows only the mutant marker near *RB1*. Does that pattern require a deletion?

> **Check your prediction.** No. Mitotic recombination or loss followed by duplication can leave two copies with one allele identity.

In 1983 Webster Cavenee, Thaddeus Dryja and colleagues tested this with DNA markers that differ between the two copies of chromosome 13. In several patients heterozygous at those markers in normal tissue, the tumor showed only one allele. The patterns fitted mitotic recombination, or nondisjunction with loss of the wild-type homolog. The second hit was often chromosomal, and LOH in tumor DNA became a way to find suppressor genes in other cancers.

*Figure (AI-generated illustration).* A cell with one mutant and one working RB1 allele can lose the working one by deletion, by losing the whole chromosome, by losing it and duplicating the remaining one, or by mitotic recombination. Each route removes the two-different-alleles state. Image: a heterozygous cell with a pair of chromosomes carrying one mutant allele (orange) and one wild-type allele (green). Below, four routes start from that cell: deletion of the wild-type segment, loss of the whole wild-type chromosome, loss followed by duplication of the mutant chromosome, and mitotic recombination. Each ends in a gold-outlined cell with only mutant alleles, shown in a Result box.

## Instability and clonal evolution

The same lineage logic scales from one retinal cell to competing subclones in a tumor. A tumor is usually a **clone**, the descendants of one cell. In 1976 Peter Nowell proposed that tumors evolve: acquired genetic variability lets more aggressive sublines be selected. Treatment can fail when a resistant subline emerges. As in bacteria under an antibiotic, mutation supplies variants and selection keeps those that divide more or die less.

**Genome instability** raises the supply. Mutations in DNA-repair genes tend to cause further mutations in other genes. Cells lacking mismatch repair, as in Lynch syndrome tumors, accumulate copying errors in short repeats. Loss of BRCA1 or BRCA2 impairs repair of double-strand breaks by homologous recombination (see [DNA repair and recombination](https://stemhop.com/lessons/dna-repair-and-recombination/) and [mutation](https://stemhop.com/lessons/mutation/)). Faulty chromosome segregation produces whole-chromosome gains and losses, and chromothripsis can produce many clustered rearrangements in one catastrophic event.

**Predict.** Does losing mismatch repair directly make every new mutation advantageous, or does it mainly change the supply of variants?

> **Check your prediction.** It raises the supply. Selection favors lineages whose drivers improve growth or survival, while passengers carried by those lineages can hitchhike with them.

Colorectal tumors show the accumulation. RAS mutations were found far more often in larger adenomas and in carcinomas than in small adenomas, and the changes accumulated as tumors progressed (Vogelstein and colleagues, 1988). Eric Fearon and Vogelstein’s 1990 model stressed the accumulation of changes over their exact order; it is a colorectal model, not a fixed sequence for every tumor.

Back to the one idea: instability creates more candidates, and growth or survival decides which lineages expand. In whole cancer genomes from many tumor types, each with matched normal tissue, the Pan-Cancer Analysis of Whole Genomes consortium identified an average of 4.6 drivers per tumor with current knowledge. That figure depends on the rules used to call drivers. Selection also works before cancer, in clones of normal human esophagus; a selected clone is not automatically a cancer.

## Reading a tumor genome

All those competing lineages end up mixed in one tumor sample. Can its reads still show which lineage carries a change?

**Film transcript: Reading a Tumor Family Tree**

### Film transcript: Reading a Tumor Family Tree

The first film followed DNA changes through one expanding lineage. How can mixed DNA reads reveal which tumor lineage carries a change? Start with that same clay-colored family tree. An early clay marker appears near its trunk. Every later branch inherits it.

Later, one branch gains a second, square marker. Only that branch carries it, so it is a subclone. The trunk marker is clonal because every tumor branch carries it. The pattern records ancestry, even when the sample mixes all branches together. Now place a matched-normal sample beside the tumor. It comes from the same person, often from blood. A variant found only in tumor is usually somatic. A variant found in both samples is usually germline, most often inherited. The word usually matters. Here is a gold variant in both tumor and matched normal.

Predict: did it most likely enter this person's cells before the tumor lineage began, or after one tumor branch formed? Most likely, it was present before the tumor lineage began. So it is usually germline, whether inherited or newly formed in an egg or sperm. The matched normal gives the timing clue. Tumor data alone cannot reliably separate that history from a somatic change. Variant allele fraction, or VAF, is the fraction of reads carrying a variant. A clonal variant can still sit below one half.

Normal cells dilute the tumor reads. Copy gains, losses, and loss of heterozygosity also change the number of variant and nonvariant copies. Purity is the fraction of cells in the sample that are tumor cells. For a heterozygous clonal variant in a two-copy region, expected VAF is purity times one half. The shortcut also assumes normal cells lack the variant. It fails after copy changes or loss of the other allele, or when only a subclone carries it. So read the evidence in order.

Compare tumor with matched normal. Ask which lineages carry the variant. Then count mutant copies against all copies. Purity, copy number, and read depth limit the inference. The result is a family-tree estimate, not a perfect replay. A high or low fraction is not a verdict by itself. Read it with the matched normal and the sample's copy structure. Different branch histories can produce similar fractions, so the supporting clues matter. That uncertainty belongs in the interpretation. Together, those clues connect mixed sequencing reads back to the expanding cell lineages that produced them.

From the film

- Variant fractions trace DNA changes through expanding tumor cell lineages.
- A matched normal helps separate variants that are usually germline from somatic variants.
- A clonal variant is in every tumor cell; a subclonal variant is in only one branch.
- Purity and copy number shape the variant fraction measured in a tumor sample.

The second film compared the tumor with a **matched normal** sample, often blood, from the same person, and read each variant’s **variant allele fraction** (VAF), the fraction of reads carrying it, against the sample’s **purity**, the fraction of cells that are tumor cells (method in the [sequencing lesson](https://stemhop.com/lessons/sequencing-and-genomes/)).

A variant in both samples is usually germline, most often inherited and rarely new in the egg or sperm, but blood is not a perfect normal. Blood-cell clones that expand with age carry somatic mutations, and those cells can also enter the tumor sample.

*Figure (AI-generated illustration).* Tumor and matched-normal sequencing separates variants seen in both samples, which are usually germline, from variants seen only in the tumor, which are usually somatic; purity and copy number then shape the measured VAF. Image: two sample vials, a matched normal of blood cells and a tumor sample that mixes tumor and normal cells. Under them a gold variant appears in both and a clay variant appears only in the tumor, labelled germline and somatic.

> **expected VAF (heterozygous, all tumor cells, two copies) = purity × 0.5**

When any of the shortcut’s four conditions fails (heterozygous, in every tumor cell, absent from normal cells, two copies), count mutant copies over all copies in the mixed sample, as the design problem does.

Genotype now shapes diagnosis. In chronic myeloid leukemia, the 9;22 translocation makes the BCR-ABL kinase that imatinib inhibits (see [drugs against a part](https://stemhop.com/lessons/drugs-against-a-part/)). In a 2021 study of acute myeloid leukemia and myelodysplastic syndromes, [whole-genome sequencing](https://stemhop.com/methods/next-generation-sequencing/) was fast enough to change the genetic risk category for some patients.

### Design problem

A colorectal tumor sample is estimated at 60% tumor cells. Tumor and matched-normal sequencing gives: KRAS G12D at VAF 0.30 in the tumor; TP53 R175H at VAF 0.60, with the other TP53 allele lost; PIK3CA at VAF 0.08; and a BRCA2 frameshift at VAF 0.50 in normal tissue and 0.80 in the tumor. Assume two copies of each region unless the data say otherwise. Which variants are inherited, which are in every tumor cell, and which are in a subclone? Why is the matched normal needed?

> **One way to do it.** In this simplified problem, reads sample DNA copies evenly.
>
> **KRAS.** If every tumor cell has one mutant and one wild-type copy, and normal cells have none, the expected VAF is 0.6 × 0.5 = 0.30, as observed: a heterozygous, clonal variant.
>
> **TP53.** If tumor cells retain two mutant copies, every tumor-cell read is mutant: 0.6 × 1.0 = 0.60, as observed. Had the wild-type allele been deleted instead, tumor cells would carry one copy and normal cells two, giving mutant over all copies: (0.6 × 1) / (0.6 × 1 + 0.4 × 2) = 0.43. So 0.60 fits clonal, copy-neutral LOH, such as mitotic recombination, under these assumptions.
>
> **PIK3CA.** If it is heterozygous, a clonal variant would sit at 0.30; 0.08 / 0.30 = 0.27, so about 27% of tumor cells carry it: a subclone that arose later.
>
> **BRCA2.** A VAF of 0.50 in normal tissue fits a heterozygous germline allele, most likely inherited; testing the parents would show whether it is new. In the tumor, 0.6 × 1.0 + 0.4 × 0.5 = 0.80 fits two mutant copies in tumor cells and one of each in normal cells: copy-neutral LOH, as for TP53. A deletion of the wild-type copy would instead give (0.6 × 1 + 0.4 × 1) / (0.6 × 1 + 0.4 × 2) = 0.71. Either route supplies a second hit in a gene already present in one-hit form.
>
> **The matched normal.** Tumor data alone cannot separate an inherited BRCA2 allele from a somatic one, or set aside the many harmless inherited variants every person carries. These are inferences about one sample, not clinical advice.

## Going deeper

### The two-hit arithmetic in full

**Worked problem.** Assume that in a carrier of one mutant *RB1* allele each tumor arises from an independent second hit, so the number of tumors per eye follows a Poisson distribution with mean m = 1.5 (3 per person, Knudson’s approximate figure), and the eyes are independent. What fractions of carriers have no tumor, a tumor in one eye only, and tumors in both eyes?

Step 1. The Poisson probability of zero events is e−m.

> **P(no tumor in one eye) = e−1.5 = 0.223**

Step 2. So P(at least one tumor in an eye) = 1 − 0.223 = 0.777.

Step 3. No tumor in either eye: 0.223 × 0.223 = 0.050, which equals e−3. About 5% stay tumor free, so penetrance is about 95%.

Step 4. Tumors in both eyes: 0.777 × 0.777 = 0.604.

Step 5. A tumor in one eye only, where either eye can be the affected one: 2 × 0.223 × 0.777 = 0.347.

Check: 0.050 + 0.604 + 0.347 = 1.001, which is 1 within rounding. About one carrier in twenty has no tumor yet can pass the allele on.

If a nonhereditary case’s expected number of tumors per eye were 0.0001, a tumor in each eye would have a chance of about 1 in 100 million.

### Who found what, and when

In 1982 several laboratories, among them those of Mariano Barbacid, Robert Weinberg and Michael Wigler, reported in *Nature* the codon 12 valine-for-glycine change described above; the slower hydrolysis was measured in 1984 and the GAP effect in 1987. Riccardo Dalla-Favera and colleagues mapped c-myc to chromosome 8 in 1982.

### Cohort sizes and percentages

In a 1988 series of 172 specimens, Bert Vogelstein and colleagues found RAS mutations in 9% of adenomas smaller than 1 cm, 58% of larger adenomas and 47% of carcinomas. The Pan-Cancer Analysis of Whole Genomes consortium examined 2,658 whole cancer genomes from 38 tumor types, each with matched normal tissue. In the 2021 leukemia study, [whole-genome sequencing](https://stemhop.com/methods/next-generation-sequencing/) in 117 consecutive patients took a median of five days and changed the genetic risk category for 19 of them.

---

From STEMhop (https://stemhop.com), free lessons by Christopher Deppmann. Lesson text © the authors. Practice questions: https://stemhop.com/lessons/cancer-genetics/
